FDA Provides Emergency Use Authorisation for Serological Test to Identify COVID-19 Antibodies
May 11 2020 Read 844 Times
PerlinElmer Inc has announced that the US Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for Euroimmun’s (a PerkinElmer company) Anti-SARS-CoV-2 ELISA (IgG) serology test. Clinical laboratories certified to perform high complexity tests under Clinical Laboratory Improvement Amendments (CLIA) can immediately begin using this ELISA for the detection of antibodies of the immunoglobulin class G.
Serological tests detect antibodies in the blood and are detected when an immune reaction to the pathogen has already taken place. These tests can determine who had previously been infected with COVID-19 (2-4 weeks or more prior to testing) and may have developed immunity. How long antibodies last and whether they are protective is being actively studied. The Euroimmun Anti-SARS-CoV-2 ELISA (IgG) is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The Euroimmun Anti-SARS-CoV-2 ELISA (IgG) has 99% specificity and 100% sensitivity after 21 days following the onset of symptoms.
“Leading with science is a fundamental part of our DNA at PerkinElmer, and the Euroimmun team recognised early on that understanding the pathogenesis of COVID-19 from a cellular biology level is paramount to developing a highly accurate and reliable antibody test,” said Prahlad Singh, President and Chief Executive officer, PerkinElmer. “As a result, the antigen used in the Euroimmun Anti-SARS-CoV-2 ELISA (IgG), the spike protein S1 domain, is more likely to reflect virus neutralising antibodies than antibodies to N capsid nucleoprotein. This is also supported by the fact that most of the COVID-19 vaccine development programs in the US and worldwide have chosen the spike protein as their target.”
“It is possible that 50% or more of people who have been infected with COVID-19 might not display symptoms, making it difficult to identify those who have previously contracted COVID-19,” said Prahlad Singh. “That’s why serological testing that utilises an antigen highly specific to SARS-CoV-2 is such an important tool in understanding how pervasive this virus is.”
Euroimmun has the capacity to manufacture millions of assays per month. Since March, it has already started shipping its Anti-SARS-CoV-2 ELISA (IgG) to leading laboratories across the globe. Euroimmun intends to further build production capacity to meet heightened demand.
More information online
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Ambient Ionisation MS and GC-MS Analysis and Identification of Aroma Compounds in Agave Based Alcoholic Beverages - How a Chromatographic Method is More Than a Sep...
View all digital editions
Sep 29 2020 Utrecht, Holland
Oct 06 2020 Lagos, Nigeria
Oct 06 2020 Digital Forum
Oct 07 2020 Lyon, France
Oct 07 2020 Lausanne, Switzerland